Swiss National Bank
CTKB icon

Swiss National Bank’s Cytek Biosciences CTKB Stock Holding History

Swiss National Bank’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-212,100
Closed -$721K – 2330
2025
Q2 		$721K Hold
212,100
– – ﹤0.01% 2251
2025
Q1 		$851K Sell
212,100
-6,700
-3% -$34.7K ﹤0.01% 2199
2024
Q4 		$1.42M Hold
218,800
– – ﹤0.01% 2048
2024
Q3 		$1.21M Hold
218,800
– – ﹤0.01% 2128
2024
Q2 		$1.22M Buy
218,800
+4,800
+2% +$28.8K ﹤0.01% 2068
2024
Q1 		$1.44M Sell
214,000
-14,500
-6% -$115K ﹤0.01% 2027
2023
Q4 		$2.08M Buy
228,500
+34,600
+18% +$218K ﹤0.01% 1802
2023
Q3 		$1.07M Buy
193,900
+17,000
+10% +$136K ﹤0.01% 2208
2023
Q2 		$1.51M Buy
176,900
+31,300
+21% +$281K ﹤0.01% 2067
2023
Q1 		$1.34M Sell
145,600
-17,000
-10% -$183K ﹤0.01% 2077
2022
Q4 		$1.66M Buy
162,600
+4,500
+3% +$60.5K ﹤0.01% 2018
2022
Q3 		$2.33M Hold
158,100
– – ﹤0.01% 1765
2022
Q2 		$1.7M Buy
+158,100
New +$1.57M ﹤0.01% 2038

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swiss National Bank's CTKB Position: Q3 2025 in Review

Swiss National Bank sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 212,100 shares — an estimated $721K sold.

Swiss National Bank first reported a position in CTKB in Q2 2022 and held it in 13 quarters. The position peaked at $2.33M in Q3 2022. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • Swiss National Bank reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
  • Swiss National Bank sold 212,100 Cytek Biosciences shares in Q3 2025, an estimated $721K.
  • Swiss National Bank first reported a position in Cytek Biosciences in Q2 2022 and held it in 13 quarters.
  • Swiss National Bank's Cytek Biosciences position peaked at $2.33M in Q3 2022.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on Swiss National Bank's 13F filing for Q3 2025, filed 13 Nov 2025.